Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05201404 · ClinicalTrials.gov registry record · Phase 3
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
A Phase 3 study of Hepatocellular Carcinoma and Cirrhosis, sponsored by Can-Fite BioPharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 471
- Enrollment target
- 20
- Study locations
NCT05201404: Recruiting Phase 3 study of Hepatocellular Carcinoma and Cirrhosis, sponsored by Can-Fite BioPharma.
NCT05201404 is a Phase 3 study of Hepatocellular Carcinoma and Cirrhosis that is actively recruiting participants, run by Can-Fite BioPharma. The registered enrollment target is 471 participants, above the 254-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (85% higher). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05201404, a Phase 3 study of Hepatocellular Carcinoma and Cirrhosis, is actively recruiting participants, sponsored by Can-Fite BioPharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 471 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.
Primary Outcome
Median duration of survival
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Namodenoson
Study Locations (20)
Other
- 841 University Clinical Centre of Republic of Srpska - Banja Luka
- 843 University Clinical Hospital Mostar - Mostar
- 842 University Clinical Centre Sarajevo - Sarajevo
- 831 Dept of Medical Oncology, Complex Oncology Ctr - Burgas EOOD - Burgas
- 835 First Department of Medical Oncology, Gastroenterology and Pulmology, Complex Oncology Center - Plovdiv EOOD, Plovdiv - Plovdiv
- Medical Center Leo Clinic EOOD Plovdiv - Plovdiv
- 834 Medical Oncology Dept, Univ Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski" EAD, Sofia - Sofia
- 518 Rabin Medical Center Beilinson Hospital - Petah Tikva
- 872 IMSP Institute of Oncology - Chisinau
- Site 858 - Koszalin
- Site 852 - Krakow
- Site 857 - Mysłowice
- Site 859 - Przemyśl
- Site 855 - Warsaw
- Site 850 - Wroclaw
- 802 Institutul Regional de Gastroenterologie si Hepatologie - Cluj-Napoca
- 807 IOCN, Medical Oncology - Cluj-Napoca
- 809 Spitalul Clinic Judetean de Urgenta Constanta Oncology Dept - Constanța
- 801 Oncology Center "Sf. Nectarie" Medical Oncology - Craiova
Texas
- Site 881 - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 471 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2026-10 |
| Phase | Phase 3 |
What NCT05201404 shows while recruiting
NCT05201404 is an interventional study that assigns participants to a tested intervention. The registered 471 participants enrollment target is mid-sized for trials with a published cap, above the 254-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (85% higher).
The record links to 2 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05201404 names 20 study sites across 2 states, led by Other, Texas.
Frequently Asked Questions
What is clinical trial NCT05201404 about?
NCT05201404 is a clinical study titled "Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis". This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.
What is the current status of trial NCT05201404?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 471 participants. The study started on 2023-03-15. Estimated completion is 2026-10.
What conditions does trial NCT05201404 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Cirrhosis.
What interventions are being tested in trial NCT05201404?
The interventions under investigation include: Placebo (DRUG), Namodenoson (DRUG).
Who is sponsoring clinical trial NCT05201404?
This trial is sponsored by Can-Fite BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05201404 being conducted?
This trial has 20 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05201404's enrollment target sits among peer trials
471 29th of 145 higher than 117 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RECRUITING · Phase 3
-
Evaluating Novel Therapies in ctDNA Positive GI Cancers
RECRUITING · Phase 3
-
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
ACTIVE NOT RECRUITING · Phase 3
-
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
ACTIVE NOT RECRUITING · Phase 3
-
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03010150 · 471 participants
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
- NCT06375083 · 472 participants · Phase 2
Computerized Cognitive Behavioral Therapies for Suicide Prevention and Depression
- NCT06947187 · 472 participants · NA
Vaccine Confidence and Infodemic in Southeast Asia's Nusantara Sociocultural Sphere
- NCT07199517 · 472 participants · NA
Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmotivated to Quit
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI